DigestRedComo funciona
Red
/
Empresas
Sa
No verificado

Samsung Bioepis Co., Ltd.

Sobre qué escribimos

BiotecnologíaFarmacéuticaIndustriaSaludSanidad

15 Comunicados de prensa

Ver todos los comunicados de prensa
02/12/2025
Biotecnología
Salud
Farmacéutica
Óptica
Industria
Pre-filled Syringe Presentation of BYOOVIZ®, Samsung Bioepis' Biosimilar to Lucentis (Ranibizumab), Gains European Approval
Fuente
Samsung Bioepis Co., Ltd.
Editor
Business Wire
1.00
0
01/12/2025
Industria
Biotecnología
Farmacéutica
Salud
Oncología
Samsung Bioepis Announces Launch of Denosumab Biosimilars, OBODENCE™ and XBRYK™, in Europe
Fuente
Samsung Bioepis Co., Ltd.
Editor
Business Wire
1.00
0
06/11/2025
Biotecnología
Farmacéutica
Salud
Sanidad
Mercado laboral
Industria
Samsung Bioepis Reaches Settlement Agreement for PYZCHIVA® (ustekinumab) in Europe
Fuente
Samsung Bioepis Co., Ltd.
Editor
Business Wire
1.00
0
29/10/2025
Mercado laboral
Industria
Salud
Ciencia
Farmacéutica
Óptica
Biotecnología
Samsung Bioepis to Commercialize BYOOVIZ® (ranibizumab) in Europe from January 2026
Fuente
Samsung Bioepis Co., Ltd.
Editor
Business Wire
1.00
0
23/10/2025
Biotecnología
Farmacéutica
Salud
Sanidad
Análisis de Mercados
Industria
Samsung Bioepis Releases Fourth Quarter 2025 US Biosimilar Market Report Providing Annual Biosimilar Trends and Future Market Trajectory
Fuente
Samsung Bioepis Co., Ltd.
Editor
Business Wire
1.00
0
20/10/2025
Samsung Bioepis And Phrontline Announce a Global Strategic Partnership to Advance Best-in-Class Antibody-Drug Conjugate Therapeutics for Solid Tumors
Fuente
Samsung Bioepis Co., Ltd.
Editor
Business Wire
1.00
0
21/07/2025
Biotecnología
Sanidad
Higiene alimentaria
Salud
Farmacéutica
Análisis de Mercados
Samsung Bioepis Releases Third Quarter 2025 US Biosimilar Market Report Exploring the Most-Favored-Nation (MFN) Policy and its Impact on Biosimilars
Fuente
Samsung Bioepis Co., Ltd.
Editor
Business Wire
1.00
0
17/07/2025
Salud
Sanidad
Farmacéutica
Óptica
Biotecnología
Mercado laboral
Industria
Samsung Bioepis Enters into a Partnership with Harrow for Commercialization of Ophthalmology Biosimilars Portfolio in the United States
Fuente
Samsung Bioepis Co., Ltd.
Editor
Business Wire
1.00
0
14/07/2025
Industria
Salud
Sanidad
Farmacéutica
Biotecnología
Samsung Bioepis' European Whitepaper Proposes Solutions to Bridge Policy Gaps that Hinder Healthy Market Competition and Timely Access to Biosimilar Medicines
Fuente
Samsung Bioepis Co., Ltd.
Editor
Business Wire
1.00
0
12/06/2025
Salud
Medicina - Varios
Ciencia
Farmacéutica
Cardiología
Biotecnología
Eventos
Industria
Análisis de Mercados
Samsung Bioepis Presents Long-Term Safety Data of EPYSQLI™ (Eculizumab) in PNH at the European Hematology Association (EHA) Congress 2025
Fuente
Samsung Bioepis Co., Ltd.
Editor
Business Wire
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0